First baby born in Malaysia using innovative assisted reproductive technology

A US fertility company has announced the birth of the first baby in Malaysia using a new assisted reproductive technology.
The healthy baby boy weighed 3.53 kg and was born on November 11, 2022 at Tuanku Mizan Military Hospital in Kuala Lumpur.
Physicians at Advanced Reproductive Centre (ARC), at Hospital Canselor Tuanku Muhriz (HCTM), at the National University of Malaysia conducted the IVC procedure using an innovative medical device developed by INVO Bioscience.
According to the company, INVOcell device allows fertilisation and early embryo development to take place in vivo within the woman’s body, providing patients a more natural, intimate, and affordable experience in comparison to other assisted reproductive technology treatments.
The device aims to expand access to advanced fertility treatment, as research shows that an increasing number of patients are unable to access treatment.
“We couldn’t be more pleased to have been a part of this family’s journey towards parenthood,” said Steve Shum, CEO of INVO Bioscience.
“The INVOcell solution is playing a key role in providing families across the world an alternative method to parenthood by leveraging its innovative medical device to allow fertilisation and early embryo development to take place in vivo within the woman’s body – an approach that provides for affordable, high-quality, patient-centred fertility care.”
The patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF that took place at ARC at HCTM. The study was published in the International Journal of Environmental Research and Public Health.
Key findings included:
- The fertilisation rate and good embryo quality were comparable between INVOcell and cIVF.
- Although both methods produce similar fertilisation rates and good-quality embryos, the blastulation rates were better in the INVOcell group.
- INVOcell can be used as an alternative method for reproductive treatment in carefully selected patients without jeopardizing outcomes.
- cIVF is costly and not applicable in most rural and district areas, therefore, the INVOcell can be utilised as a cost-effective alternative to cIVF without sacrificing comfort and outcomes.
“We are pleased to see the published findings from Malaysia demonstrating the attributes of INVOcell,” Shum added.
“We believe Malaysia, with an approximate population of more than 32 million, represents an attractive opportunity for INVOcell.
“This publication follows the recent award INVOcell received as a new and innovative fertility treatment, with IVC formally being made available to patients at HTCM, one of the five university hospitals in Malaysia, and currently the highest volume fertility centre in the country.”
He added: “We look forward to continuing our work with key partners in Malaysia to bring our innovative advanced fertility treatment to the people of Malaysia.”
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.









